T1	Participants 15 93	Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion:
T2	Participants 284 364	patient-reported visual function in symptomatic VMA/vitreomacular traction (VMT)
T3	Participants 624 654	patients with symptomatic VMA.
T4	Participants 918 1032	A total of 652 patients with symptomatic VMA/VMT, including when associated with a macular hole 400 Î¼m or smaller
T5	Participants 1118 1165	INTERVENTIONS Patients with symptomatic VMA/VMT
T6	Participants 1685 1752	studies, 464 patients received ocriplasmin and 188 received placebo
T7	Participants 2896 2919	patient-reported visual
